HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Victoria's Secret Launches Dream Angels Heavenly As Lingerie Extension

This article was originally published in The Rose Sheet

Executive Summary

Victoria's Secret is introducing Dream Angels Heavenly fragrance and body collection as the company's first extension of its Dream Angels lingerie line. Five skin care products will be available October 15, followed by two more items in November.

You may also be interested in...



Victoria's Secret Tells Consumers To Think Pink In Extensive Ad Campaign

Victoria's Secret will support the April launch of Pink, its first fragrance to debut outside the Dream Angels collection, with an "ever changing" print ad campaign. The "Think Pink" ads feature supermodel Gisele Bundchen.

Victoria's Secret Tells Consumers To Think Pink In Extensive Ad Campaign

Victoria's Secret will support the April launch of Pink, its first fragrance to debut outside the Dream Angels collection, with an "ever changing" print ad campaign. The "Think Pink" ads feature supermodel Gisele Bundchen.

Dream Angels Heavenly Sales Total $42 Mil. In 4Q, National Ads Planned

Victoria's Secret will build on the success of its Dream Angels Heavenly fragrance with the company's first beauty-oriented national advertising campaign, Intimate Beauty CEO Robin Burns said. The women's scent generated $42 mil. in sales from mid-October to the end of parent company Intimate Brand's FY ended Jan. 29.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS007252

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel